{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-133348","form_type":"8-K","ticker":"CPRX","cik":"0001369568","company_name":"CATALYST PHARMACEUTICALS, INC.","filed_at":"2025-06-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.082969+00:00","generated_at":"2026-05-20T02:34:17.193376+00:00","sec_items":["8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Catalyst Pharma appoints Dr. William Andrews as CMO; Dr. Ingenito retires","bullets":["Gary Ingenito retired as Chief Medical and Regulatory Officer effective June 1, 2025; no disagreement with management.","William Andrews appointed as new Chief Medical Officer effective June 2, 2025, reporting to CEO Richard Daly.","Andrews brings 24 years of biopharma experience, including CMO roles at Flexion, Akcea, and Acer Therapeutics.","Ingenito will serve as a consultant to assist with the transition."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-133348","json":"https://secwatch.observer/filing/0001193125-25-133348.json","markdown":"https://secwatch.observer/filing/0001193125-25-133348.md","text":"https://secwatch.observer/filing/0001193125-25-133348.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1369568/000119312525133348/0001193125-25-133348-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1369568/000119312525133348/d17589d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T02:34:17.193376+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}